Patents by Inventor Christopher John Stanley

Christopher John Stanley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8603771
    Abstract: Micro-organisms, including fungi, viruses and bacteria such as Mycobacteria and/or fragments of micro-organisms such as cell wall components present in an aqueous liquid are captured to a solid surface by adding to the liquid a sufficient quantity of a water soluble polymer in the presence of the solid surface to displace the micro-organisms and/or fragments from the liquid to the solid surface. The surface may be provided by a bead. The water soluble polymer may be polyethyleneglycol or polyvinylpyrrolidone.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: December 10, 2013
    Assignee: Microsens Medtech Limited
    Inventors: Christopher John Stanley, Stuart Mark Wilson
  • Publication number: 20130171689
    Abstract: Micro-organisms, including fungi, viruses and bacteria such as Mycobacteria and/or fragments of micro-organisms such as cell wall components present in an aqueous liquid are captured to a solid surface by adding to the liquid a sufficient quantity of a water soluble polymer in the presence of the solid surface to displace the micro-organisms and/or fragments from the liquid to the solid surface. The surface may be provided by a bead. The water soluble polymer may be polyethyleneglycol or polyvinylpyrrolidone.
    Type: Application
    Filed: June 29, 2011
    Publication date: July 4, 2013
    Applicant: MICROSENS MEDTECH LIMITED
    Inventors: Christopher John Stanley, Stuart Mark Wilson
  • Patent number: 8383617
    Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: February 26, 2013
    Assignee: PAD Pharma Limited
    Inventors: Stuart Mark Wilson, Christopher John Stanley
  • Publication number: 20100291564
    Abstract: NAD-dependent ligase is identified as an indicator of micro-organisms in a sample. A method of detecting the presence of an NAD-dependent ligase expressing micro-organism in a sample comprises the steps of: (a) contacting the sample with a nucleic acid molecule which acts as a substrate for NAD-dependent ligase activity in the sample, (b) incubating the thus contacted sample under conditions suitable for NAD-dependent ligase activity; and (c) specifically determining the presence of a ligated nucleic acid molecule resulting from the action of the NAD-dependent ligase on the substrate nucleic acid molecule to indicate the presence of the NAD-dependent ligase expressing micro-organism. The method has a number of applications and kits for carrying out the methods are also provided.
    Type: Application
    Filed: July 9, 2008
    Publication date: November 18, 2010
    Applicant: MICROSEN MEDTECH LIMITED
    Inventors: Christopher John Stanley, Stuart Wilson
  • Publication number: 20100143883
    Abstract: A method for the capture from a sample of micro-organisms having a hydrophobic surface, which method includes contacting the micro-organisms with a capture reagent, which capture reagent has both a hydrophobic character whereby the capture reagent binds the micro-organisms by hydrophobic interaction therewith and a polar character, the capture reagent either being present on a surface and capturing the micro-organisms thereto, or being present in solution, the method then further including capturing the micro-organisms to a surface by binding the capture reagent to the surface by polar interaction between the surface and the capture reagent.
    Type: Application
    Filed: November 23, 2007
    Publication date: June 10, 2010
    Applicant: Microsens Medtech Limited
    Inventors: Stuart Mark Wilson, Christopher John Stanley
  • Publication number: 20100035859
    Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.
    Type: Application
    Filed: January 30, 2008
    Publication date: February 11, 2010
    Applicant: PAD Pharma Limited
    Inventors: Stuart Mark Wilson, Christopher John Stanley
  • Publication number: 20040259131
    Abstract: The invention relates to methods of detecting target molecules or the interactions between target molecules based on interactions between proximally-bound nucleic acid tags. Reagent kits for use in such methods are also provided.
    Type: Application
    Filed: April 2, 2004
    Publication date: December 23, 2004
    Applicant: Iseao Technologies Limited
    Inventors: Stuart Wilson, Christopher John Stanley
  • Patent number: 6627460
    Abstract: A novel preparative methodology yields water-soluble, cross-linked conjugates and conjugate complexes that confer an improved sensitivity in immunochemical assays, particularly in the context of lateral flow devices and in determinations of the presence or absence of small amounts of active components present in a liquid sample.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: September 30, 2003
    Assignee: Amdex A/S
    Inventors: Allan Otto Fog Lihme, Christopher John Stanley
  • Patent number: 6346378
    Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bound to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: February 12, 2002
    Assignee: PNA Diagnostics A/S
    Inventors: Christopher John Stanley, Henrik Orum, Mikkel Jorgensen
  • Publication number: 20010047077
    Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bound to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.
    Type: Application
    Filed: May 29, 1998
    Publication date: November 29, 2001
    Inventors: CHRISTOPHER JOHN STANLEY, HENRIK ORUM, MIKKEL JORGENSEN
  • Patent number: 6163714
    Abstract: An implantable sensor for use in the detection or quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: December 19, 2000
    Assignee: Torsana Diabetes Diagnostics A/S
    Inventors: Christopher John Stanley, Anders Weber
  • Patent number: 5972610
    Abstract: The present invention relates to the use of nucleic acid analogues in blocking nucleic acid amplification procedures and to diagnostic and analytical techniques based thereon. Also included are kits for use in the conduct of nucleic acid amplification reactions.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: October 26, 1999
    Inventors: Ole Buchardt, deceased, by Dorte Buchardt, legal representative, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Christopher John Stanley
  • Patent number: 5891625
    Abstract: Nucleic acid analogues such as peptide-nucleic acids (PNAs) which hybridize strongly to nucleic acids are used to inhibit nucleic acid amplification procedures such as PCR. False positives in subsequent PCR assays are prevented by hybridizing a PNA to PCR amplification products. Assays capable of discriminating between single base mutants are conducted by using a PNA hybridizing to one of the two allelic forms to inhibit a PCR amplification of that form selectively. Asymmetric PCR amplifications are carried out by starting a PCR symmetrically using like quantities of forward and reverse primers, and, once the amplification is established, disabling one primer by hybridizing a PNA thereto.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: April 6, 1999
    Inventors: Ole Buchardt, deceased, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Christopher John Stanley
  • Patent number: 5861250
    Abstract: A selected region of a nucleic acid is protected from attach by nuclease by completing to the nucleic acid a nucleic acid analogue of the PNA type. The surviving sequence may be detected in an assay, optionally after amplification. A PCR reaction may be sterilized and its product assayed by protecting a characterizing region of the product by PNA hybridization followed by nuclease degradation of unprotected nucleic acid.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: January 19, 1999
    Assignee: PNA Diagnostics A/S
    Inventors: Christopher John Stanley, Henrik Orum, Mikkell Jorgensen, Ole Basboll
  • Patent number: 5843663
    Abstract: A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bounds to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: December 1, 1998
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christopher John Stanley, Henrik Orum, Mikkel Jorgensen
  • Patent number: 5744094
    Abstract: A sterilizing method includes subjecting material, for example packaging board, to laser UV alone, or substantially simultaneously with laser IR and/or hydrogen peroxide to obtain a synergistic effect between the UV and IR and/or hydrogen peroxide, to render micro-organisms present at said material non-viable.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: April 28, 1998
    Assignee: Elopak Systems AG
    Inventors: Helge Bakketun Castberg, Karin Bergmann, Peter John Hyde, Karen Margaret Montgomery Ness, Christopher John Stanley
  • Patent number: RE38525
    Abstract: An implantable sensor for use in the detection of quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: June 8, 2004
    Assignee: Torsana Diabetes Diagnostics A/S
    Inventors: Christopher John Stanley, Anders Weber